Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04351867
Other study ID # GC202001
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date September 2020
Est. completion date June 2024

Study information

Verified date July 2020
Source Henan Cancer Hospital
Contact Ning Li, PhD
Phone 0086-13526501903
Email lining97@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was a prospective, randomized, controlled phase III clinical study to evaluate the efficacy and safety of docetaxel plus oxaliplatin and capecitabine versus oxaliplatin plus capecitabine in the treatment of gastric or gastroesophageal junction adenocarcinoma with postoperative pathological stage IIIB and IIIC.


Description:

In 2019, CSCO guidelines grade I recommend gastric or gastroesophageal junction adenocarcinoma patients, after D2 R0 resection, whose postoperative pathological stage was III treated with XELOX as an adjuvant chemotherapy. However, some retrospective clinical studies in China suggest that the 3-year DFS rate of XELOX program as an adjuvant postoperative chemotherapy program is still low, and the risk of recurrence is higher for patients with postoperative pathological stage IIIB/IIIC.In recent years, the success of the JACCRO GC-07 trial has provided evidence for the value of Taxoids in postoperative adjuvant therapy of gastric cancer. In the FLOT4 trial, the FLOT improved the DFS rate by 3 years compared with the ECF/ECX. At present, there is no clinical study data to prove whether the combined three-drug regimen can further reduce the risk of postoperative recurrence and improve the treatment effect compared with oxaliplatin combined capecitabine two-drug regimen for patients with high postoperative recurrence risk (patients with postoperative pathological stage IIIB/IIIC). Therefore, the investigators carried out this trial.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 196
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Have signed the informed consent and can comply with the visit and related procedures stipulated in the program

- Age =18 years old and =75 years old

- D2 radical resection was performed within 21-60 days before the beginning of the first cycle of chemotherapy in this clinical study

- Preoperative neoadjuvant chemotherapy was not performed and Gastric and gastroesophageal junction adenocarcinoma (including signed-ring cell carcinoma, mucinous adenocarcinoma, and hepatoid adenocarcinoma) at stage IIIB and IIIC were confirmed by postoperative pathological staging. Note: the presence of distant metastases should be confirmed by a CT or MRI scan.ECT should be performed if bone metastases are suspected.If peritoneal metastases are suspected, laparoscopy should be performed

- Postoperative ECOG score was 0 or 1

- Leukocyte = 4×109/L, platelet = 100×109/L without blood transfusion, neutrophil absolute value (ANC) = 1.5×109/L without granulocyte stimulating factor treatment, and hemoglobin = 90 g/L

- Bilirubin = 1.5 times of the upper limit of normal value, glutamic oxalacetic transaminase and glutamic-pyruvic transaminase = 2.5 times of the upper limit of normal value

- Serum creatinine = 1.5 times the upper limit of normal value, or GFR>45 ml/min

- Serum albumin = 25 g/L (2.5g /dL)

- INR or PT = 1.5 times ULN

- Hepatitis b surface antigen positive patients need to be tested for hepatitis b DNA virus quantitative detection, only < the upper limit of the normal detection value can be included in the group, and should long-term use of anti-hepatitis b drugs

- Tumor specimens can be provided for consultation (if the patient's surgical specimen comes from another hospital), protein and gene testing

Exclusion Criteria:

- Postoperative wound healing is poor and chemotherapy is not appropriate to start

- Recurrent patients or suspected peritoneal metastases after radical surgery

- Known DPD enzyme deficiency

- Allergy to, or history of severe allergy to, or contraindication to any of the experimental drugs or its excipients

- Patients who are expected to require major surgery during the study period

- Congenital pulmonary fibrosis, drug-induced pneumonia, organized pneumonia, or CT-confirmed active pneumonia

- Tested positive for HIV

- Active hepatitis b or c

- Only liquid diet was allowed after the operation, with BMI <18kg/m2

- Uncontrolled pain

- A history of antitumor drug therapy other than radical surgery

- Severe infection in the active stage or with poor clinical control

- Use of hormones is contraindicated

- Severe cardiovascular disease, myocardial infection or cerebrovascular accident, arrhythmia, unstable angina pectoris within 3 months before the trial

- Uncontrollable increase in blood pressure or blood sugar

- A history of other malignancies within 5 years, except for carcinoma in situ of the cervix, non-melanoma skin cancer, or stage I uterine cancer

- Distant metastases are known

- Peripheral neuropathy = NCI CTCAE grade 2

- Serum albumin < 2.5 g/dL

- Chronic enteritis

- Any other disease for which there is evidence of a need to limit the use of experimental drugs

- Participate in additional trials up to 30 days before the trial or plan to participate in additional trials while the trial is ongoing

- Receive other experimental drugs up to 28 days before the start of the trial

- Women who are pregnant or nursing, or who plan to become pregnant within five months of the end of treatment. Women of childbearing age should receive a blood/urine pregnancy test 7 days before the start of the trial

- Clinically significant active bleeding

- Patients who have trouble swallowing tablets

- Previous allogeneic bone marrow transplant or organ transplant

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
docetaxel plus oxaliplatin and capecitabine
docetaxel 50mg/? ivgtt. d1+oxaliplatin 100mg/? ivgtt. d1+capecitabine 1000mg/? bid p.o. d1-d14 q21d
oxaliplatin plus capecitabine
oxaliplatin 130mg/? ivgtt. d1+capecitabine 1000mg/? bid p.o. d1-d14 q21d

Locations

Country Name City State
China Henan Cancer Hospital Zhengzhou Henan

Sponsors (1)

Lead Sponsor Collaborator
LiNing

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary disease free survival From the date of randomization until the date of the first recorded disease recurrence, metastasis or death from any cause, whichever came first. up to three years.
Secondary overall survival From the date of randomization until the date of the first recorded death from any cause. For subjects lost to follow-up prior to death, the last follow-up time is usually calculated as the time of death. up to three years.
Secondary Adverse reaction Adverse reaction will be assessed by NCI CT CAE v5.0. up to three years.
Secondary Assessment of life quality Quality of life will be assessed using The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Cancer (QLQ-C30) and the site-specific module for gastric cancer (QLQ-STO22) . These tables will be usde together to assessed the quality of life of the patients. The higher the score, the worse the quality of life. up to three years.
See also
  Status Clinical Trial Phase
Recruiting NCT01950572 - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT02887612 - ctDNA for Prediction of Relapse in Gastric Cancer
Active, not recruiting NCT02930291 - The Effect of Preoperative Inflammation-based Scores on Postoperative Morbidity and Mortality for Laparoscopic Gastrectomy
Completed NCT02649348 - Effects of Prehabilitation in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome N/A
Recruiting NCT02310230 - An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy N/A
Active, not recruiting NCT01609309 - Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01) Phase 3
Completed NCT00375999 - Docetaxel and Epirubicin in Advanced Gastric Cancer Phase 2
Completed NCT00382720 - Docetaxel and Oxaliplatin in Gastric Cancer Phase 2
Completed NCT00980382 - A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma Phase 1/Phase 2
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Active, not recruiting NCT05602935 - Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study Phase 2
Recruiting NCT05033392 - PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer Phase 2
Completed NCT04539769 - Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes Phase 2
Active, not recruiting NCT02930278 - The Effect of Preoperative Hemotologic Markers on Postoperative Long-term and Short-term Outcomes for Laparoscopic Gastrectomy
Active, not recruiting NCT02845986 - Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer Phase 2
Completed NCT02902575 - The Safety and Feasibility of Laparoscopic-assisted Gastrectomy for Advanced Gastric Cancer After Neoadjuvant Chemotherapy N/A
Recruiting NCT04222114 - Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis Phase 3
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4
Not yet recruiting NCT05095467 - HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction Phase 2